Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 3006337 in healthy Japanese males
NCT06310005Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2024
- Primary completion
- Oct 2024
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of YH25724 (6 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Treatment-emergent Adverse Events at 9 weeks. Started Apr 2024; status: completed.
02
Drugs
YH25724
Beyond the preview
Go deeper on NCT06310005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06310005.